Related Experiment Video

Updated: May 31, 2026

Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles
07:54

Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles

Published on: November 5, 2020

Comparative modelling of human β tubulin isotypes and implications for drug binding

J Torin Huzil1, Richard F Ludueña, Jack Tuszynski

  • 1Department of Oncology, University of Alberta, Edmonton, AB, T6G 2J1, Canada.

Nanotechnology
|July 6, 2011
PubMed

Insights

Researchers analyzed ten human beta-tubulin isotypes to find differences in drug-binding sites. This could lead to new cancer drugs that target only cancer cells, reducing side effects.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Tubulin is a key target for anti-mitotic drugs used in cancer chemotherapy, affecting microtubule dynamics.
  • Current tubulin-binding drugs like taxanes and Vinca alkaloids lack specificity, causing toxicity to both cancerous and healthy cells.
  • Tubulin isotypes offer potential for developing targeted therapies with reduced side effects.

Purpose of the Study:

  • To analyze ten human beta-tubulin isotypes.
  • To identify differences in the binding sites of established tubulin-binding drugs: paclitaxel, colchicine, and vinblastine.

Main Methods:

  • Comparative analysis of ten human beta-tubulin isotypes.
  • Examination of previously characterized drug-binding sites.

Main Results:

  • Differences were identified within the paclitaxel, colchicine, and vinblastine binding sites across the ten human beta-tubulin isotypes.
  • This isotype-specific variation in binding sites provides a basis for developing more selective anti-tubulin agents.

Conclusions:

  • Understanding beta-tubulin isotype differences is crucial for designing novel chemotherapeutic drugs.
  • Targeting specific tubulin isotypes could lead to more effective cancer treatments with fewer adverse effects.

More Related Videos

Optimizing Tubulin Yield from Porcine Brain Tissue06:30

Optimizing Tubulin Yield from Porcine Brain Tissue

Published on: October 11, 2024

Related Concept Videos

Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...